Why the study?
Is dopexamine an advance on dopamine and dobutamine for the short-term treatment of patients with low cardiac output after heart surgery?
Is dopexamine an advance on dopamine and dobutamine for the short-term treatment of patients with low cardiac output after heart surgery?
This article reviews whether dopexamine offers advantages over dopamine and dobutamine for treating low cardiac output after cardiac surgery.
Dopexamine's role remains unproven; leaves open whether it offers advantages over dopamine or dobutamine after cardiac surgery.
After heart surgery there may be many hours in which cardiac output is reversibly depressed. Treatment is given to enhance output and to ensure an adequate blood supply to vital organs. Drugs used in this situation commonly include dopamine and dobutamine. Dopexamine (Dopacard-Speywood) is a dopamine analogue which in the UK is licensed only for the short-term treatment of patients with low cardiac output after heart surgery. The manufacturer claims that dopexamine is particularly effective in promoting renal and splanchnic blood flow. Is dopexamine an advance on dopamine and dobutamine?
No takes yet. Share an insight, caveat, or question.
A 1995 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: